Image

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)

Recruiting
18 years of age
Both
Phase 1/2

Powered by AI

Overview

This is an open-label, multicenter study to evaluate safety and tolerability, determine the RP2Ds of tafasitamab alone in Japanese participants with R/R NHL, or to evaluate efficacy and safety of tafasitamab in combination with lenalidomide in Japanese participants with R/R DLBCL, or tafasitimab in combination with lenalidomide plus R-CHOP in Japanese participants with previously untreated DLBC, or tafasitimab in combination with lenalidomide in Japanese participants with previously R/R DLBC.

Eligibility

Inclusion Criteria:

  • Group 1 only: Biopsy-proven participants with relapsed or refractory NHL of DLBCL, FL or MZL.
  • Groups 3, 4a and 5 only: Biopsy-proven participants with relapsed or refractory DLBCL.
  • Groups 2 and 6 only: Biopsy-proven participants with DLBCL and another select lymphoid neoplasms.
  • Participants must have at least 1 bi-dimensionally measurable lesion.
  • ECOG performance status of 0 to 2.
  • Participants with protocol defined laboratory criteria at screening as defined in the protocol.
  • Group 1 only:
        Received at least 1 previous systemic therapy line for the treatment of NHL. At least 1
        previous therapy line must have included a CD20-targeted therapy (eg, RTX).
          -  Groups 2, 3, 4a and 6 only:
        Received at least 1, but no more than 3, previous systemic therapy lines for the treatment
        of DLBCL. At least 1 previous therapy line must have included a CD20-targeted therapy (eg,
        RTX).
          -  Group 5 only: Participants must have:
               1. Untreated DLBCL.
               2. Ann Arbor Stage III to IV.
               3. IPI status of 3 to 5 or age-adjusted IPI 2-3 (in Group 5 only).
               4. Appropriate candidate for R-CHOP.
               5. LVEF of ≥ 50%, assessed by echocardiography.
          -  Willingness to avoid pregnancy or fathering children.
          -  In the opinion of investigator, the participant must:
               1. Not have a history of noncompliance in relation to medical regimens or be
                  considered potentially unreliable and/or uncooperative.
               2. Be able to understand the reason for complying with the special conditions of the
                  pregnancy prevention risk management plan and give written acknowledgement of
                  this.
        Exclusion Criteria:
          -  Any other histological type of lymphoma.
          -  History of prior non-hematologic malignancy.
          -  Congestive heart failure requiring use of ongoing maintenance therapy for
             life-threatening ventricular arrhythmias.
          -  Participants with known positive test result for hepatitis C, and hepatitis B.
          -  Known seropositive for or history of active viral infection with HIV.
          -  Known active bacterial, viral, fungal, mycobacterial, or other infection at screening.
          -  Known CNS lymphoma involvement - present or past medical history.
          -  History or evidence of clinically significant cardiovascular, CNS and/or other
             systemic disease that would in the investigator's opinion preclude participation in
             the study or compromise the participant's ability to give informed consent.
          -  History or evidence of rare hereditary problems of galactose intolerance, Lapp lactase
             deficiency or glucose-galactose malabsorption.
          -  History or evidence of interstitial lung disease.
          -  Vaccination with live vaccine within 21 days prior to study treatment (Note:
             throughout the study treatment period and at least 6 months after end of treatment,
             vaccination with live vaccines should be avoided).
          -  Major surgery within up to 30 days prior to signing the ICF, unless the participant is
             recovered at the time of signing the ICF.
          -  Any anticancer and/or investigational therapy within 14 days prior to the start of
             Cycle 1.
          -  Groups 2, 3, 4a, 5 and 6 only: Gastrointestinal abnormalities including the inability
             to take oral study treatment, requiring IV alimentation, or prior surgical procedure
             affecting absorption.
          -  Pregnancy or lactation.
          -  Groups 2, 3, 5 and 6 only: Participants who have history of deep venous
             thrombosis/embolism, threatening thromboembolism, stroke or known thrombophilia or are
             at a high risk for a thromboembolic event in the opinion of the investigator and who
             are not willing/able to take venous thromboembolic event prophylaxis during the entire
             treatment period if required
          -  Group 4a only: Use or expected use during the study of any restricted medications,
             including potent CYP3A4 inhibitors or inducers within 14 days or 5 half-lives
             (whichever is longer) before the date of study treatment administration
          -  Groups 1, 3, 4a and 6 only: Participants who have:
               1. Not discontinued CD20-targeted therapy, chemotherapy, radiotherapy,
                  investigational anticancer therapy, or other lymphoma-specific therapy within the
                  14 days prior to Day 1 dosing.
               2. In the opinion of the investigator, not recovered sufficiently from the adverse
                  toxic effects of prior therapies.
               3. Groups 1, 3 and 4a only: Previous treatment with CD19-targeted therapy (eg,
                  CD19-CAR-T therapies, other CD19 mAbs including bispecific and ADCs).
                  Groups 2 and 6 only: Previous treatment with tafasitamab. Note: Participants in
                  Groups 2 and 6 who have received previous CD19 directed therapy (other than
                  tafasitamab) must have CD19-positive lymphoma confirmed by a biopsy taken after
                  completing the prior CD19-targeted therapy.
               4. Groups 2, 3 and 6 only: Been previously treated with IMiDs (eg, thalidomide or
                  LEN).
               5. Group 4a only: Been previously treated with selective PI3Kδ or pan-PI3K
                  inhibitors (eg, idelalisib, copanlisib, duvelisib) and/or Bruton's tyrosine
                  kinase inhibitors (eg, ibrutinib).
               6. A history of hypersensitivity to compounds of similar biological or chemical
                  composition to tafasitamab, IMiDs, and/or the excipients contained in the study
                  treatment formulations (citric acid monohydrate, polysorbate 20, sodium citrate
                  dehydrate and trehalose dihydrate).
               7. Undergone ASCT within the period ≤ 3 months before the signing of the ICF.
                  Participants who have a more distant history of ASCT must exhibit full
                  hematological recovery before enrolment into the study.
               8. Undergone previous allogenic stem cell transplantation.
               9. Concurrent treatment other anticancer or experimental treatments.
          -  Group 5 only: Participants who have:
               1. A history of radiation therapy to ≥ 25% of the bone marrow for other diseases or
                  history of anthracycline therapy.
               2. A history of hypersensitivity or contraindication to any component of R-CHOP,
                  LEN, or compounds of similar biological or chemical composition as tafasitamab
                  and/or the excipients contained in the study treatment formulations or R-CHOP.
               3. Contraindication to any of the individual components of R-CHOP.
               4. Any anticancer and/or investigational therapy within 30 days prior to the start
                  of Cycle 1, except for permitted prephase treatment defined below.

Study details

Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma

NCT04661007

Incyte Biosciences Japan GK

15 June 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.